Similar articles

• Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.

  Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Jaffe N, et al. N Engl J Med. 1974 Nov 7;291(19):994-7. doi: 10.1056/NEJM197411072911902. N Engl J Med. 1974. PMID: 4606174 Clinical Trial. No abstract available.
• Radiation in bone sarcomas: a re-evaluation in the era of intensive systemic chemotherapy.

  Tefft M, Chabora BM, Rosen G. Tefft M, et al. Cancer. 1977 Feb;39(2 Suppl):806-16. doi: 10.1002/1097-0142(197702)39:2+<806::aid-cncr2820390715>3.0.co;2-x. Cancer. 1977. PMID: 402197
• Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.

  Jaffe N. Jaffe N. Cancer Chemother Rep. 1974 Mar-Apr;58(2):275-80. Cancer Chemother Rep. 1974. PMID: 4598245 Clinical Trial. No abstract available.
• Current therapies in osteosarcoma.

  Handelsman H, Carter SK. Handelsman H, et al. Cancer Treat Rev. 1975 Mar;2(1):77-83. doi: 10.1016/s0305-7372(75)80017-x. Cancer Treat Rev. 1975. PMID: 1102086 Review. No abstract available.
• Methotrexate revisited.

  Frei E 3rd. Frei E 3rd. Med Pediatr Oncol. 1976;2(3):227-41. doi: 10.1002/mpo.2950020303. Med Pediatr Oncol. 1976. PMID: 790144 Review. No abstract available.